[Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Терапевтический архив

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 19253720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.

  2004cited by this paper
• Histopathological evaluation of 0‐h biopsy specimens of donor kidney procured by laparoscopic donor nephrectomy

  2004cited by this paper
• Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.

  2004cited by this paper
• The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.

  2004cited by this paper
• Scientific and therapeutic advances in antiplatelet therapy

  2003cited by this paper
• TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention

  2002cited by this paper
• An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.

  2002cited by this paper
• Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

  2002cited by this paper
• Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

  2001cited by this paper
• Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

  2001cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

  2001cited by this paper
• Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes

  2001cited by this paper
• A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.

  2000cited by this paper
• Platelet GPIIb-IIIa blockers.

  1999cited by this paper
• Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

  1998cited by this paper
• Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

  1998cited by this paper
• Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

  1997cited by this paper

• No citing papers are available for this paper.